1. Technology Overview
Major public health concerns associated with the diagnosis of prostate cancer are overdiagnosis and overtreatment. The current diagnosis of prostate cancer involves a transrectal ultrasound (TRUS) guided biopsy of the prostate gland to rule out any malignancy (presence of a malignant tumour). The need for a TRUS biopsy is determined by a suspicious digital rectal examination and an increased serum prostate-specific antigen (PSA) which is the most widely used biomarker. However, this current method lacks specificity and sensitivity where a raised level of PSA could be brought about by other non-malignant medical conditions. This, unfortunately, leads to erroneous and unnecessary diagnostic intervention and radical clinical therapies. Accordingly, this invention serves to solve this problem by providing a platform for a more accurate diagnosis and discrimination of prostate cancer from non-cancer conditions via the use of specific peptide biomarkers.
2. Technology Features and Specifications
- High specificity and sensitivity
- Unique biomarkers ITIH4 and ITIL.
- Uses ratios of biomarkers (ITIH4: ITIL) for specificity.
- Compares ratios with healthy patients, patients with prostate cancer and those with benign condition for specificity
- Minimizes the diagnosis of low grade and insignificant cancers
- Ratios of ITIH4 and ITIL can discriminate prostate cancer from the most similar medical condition known as benign prostatic hyperplasia (BPH).
- Accurate discrimination of prostate cancer is often hindered by BPH, and the specificity of this invention as compared to conventional methods gives it the edge over all other diagnosis methods
3. Market Opportunity and Potential Applications
This invention has numerous strengths that capitalize on weaknesses that exist with currently used methods of diagnosis. The efficacy of this method in using ratios of the biomarkers to discriminate between healthy people, patients with benign prostatic hyperplasia and prostate cancer renders it as a suitable, more reliable alternative to conventional diagnostic methods.
4. Benefits and Impacts
This diagnosis method for prostate cancers is highly beneficial in providing a more accurate means for diagnosis and discrimination of prostate cancers. The efficiency of this method and its high specificity reduces instances of the diagnosis of low grade and insignificant cancers. This invention as a whole provides the means necessary for reducing or even overcoming the persisting problem of overdiagnosis and overtreatment in the management of prostate cancers.
5. Development Stage
Available for Licensing